会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Compounds useful in therapy
    • 化合物可用于治疗
    • US20060241125A1
    • 2006-10-26
    • US11408286
    • 2006-04-18
    • Paul BradleyKevin DackIan Marsh
    • Paul BradleyKevin DackIan Marsh
    • A61K31/506A61K31/4152C07D403/02
    • C07D231/28C07D231/18C07D401/04C07D401/06C07D403/04C07D403/06C07D413/06C07D417/06
    • Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents H, C1-6-alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substituted by CN), or Het; R3 represents OH, CN, Het, —R4—C1-6alkyl, or CONR5R6; R4 represents —CO2—, or —O—; R5 and R6 independently represent H, C1-6alkyl (optionally substituted by OR7) or C3-8cycloalkyl; R7 represents H or C1-6alkyl; Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii) one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C1-6 alkyl; R8 represents C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo; may be useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
    • 式(I)化合物或其药学上可接受的衍生物,其中:R 1表示H,C 1-6烷基,C 1-6烷基, 烷氧基,C 3-8环烷基或卤素; R 2表示H,C 1-6烷基(任选被R 3 O 3取代),苯基(任选被CN取代)或Het; R 3表示OH,CN,Het,-R 4 -C 1-6烷基或CONR 5 R 6; R 4表示-CO 2 - 或-O-; R 5和R 6独立地表示H,C 1-6烷基(任选被OR 7取代)或 C 3-8环烷基; R 7表示H或C 1-6烷基; Het表示含有(i)1-4个氮杂原子或(ii)一个或两个氮杂原子和一个氧或一个硫杂原子的五元或六元芳族杂环基,或(iii)一个或两个氧 或硫杂原子,所述杂环基团任选被一个或多个选自CN和C 1-6烷基的基团取代; R 8表示C 1-6烷基,C 1-6烷氧基,C 3-8环烷基,或 光环; R 9和R 10独立地代表H,C 1-6烷基,C 1-6烷氧基,CN CF 3或卤素; 可能有助于治疗子宫内膜异位症,子宫肌瘤(平滑肌瘤),月经过多,子宫腺肌症,原发性和继发性痛经(包括性交疼痛,dyschexia和慢性盆腔疼痛症状)或慢性盆腔疼痛综合征。
    • 2. 发明申请
    • Compounds useful in therapy
    • 化合物可用于治疗
    • US20070105909A1
    • 2007-05-10
    • US11592574
    • 2006-11-03
    • Paul BradleyKevin DackPatrick JohnsonSarah Skerratt
    • Paul BradleyKevin DackPatrick JohnsonSarah Skerratt
    • A61K31/4439A61K31/4152C07D403/02C07D231/12
    • C07D231/18C07D401/12
    • Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
    • 式(I)化合物或其药学上可接受的衍生物,其中R 1和R 3独立代表H,C 1-6烷基 C 3-8环烷基或卤素; R 2表示C 1-6烷基,CF 3或芳基; a代表1或2; R 4,R 5,R 7和R 8独立地表示H,C 1-6 C 1-6烷基,C 1-6烷氧基,CN或卤素,或R 4和R 5或R 7 和它们所连接的环连接形成芳基或杂环稠环体系; X表示C或N; Y表示CH 2或O; R 6表示H,CN或卤素,条件是当X表示N时,R 6不存在。 这些化合物可用于治疗子宫内膜异位症,子宫肌瘤(平滑肌瘤),月经过多,子宫腺肌症,原发性和继发性痛经(包括性交疼痛,dyschexia和慢性盆腔疼痛症状)或慢性盆腔疼痛综合征。
    • 3. 发明申请
    • 1H-Pyrazoles Useful In Therapy
    • 1H-吡唑有用的治疗
    • US20080085919A1
    • 2008-04-10
    • US11870451
    • 2007-10-11
    • Paul BradleyKevin DackPatrick JohnsonSarah Skerratt
    • Paul BradleyKevin DackPatrick JohnsonSarah Skerratt
    • A61K31/415A61K31/4152A61K31/4709A61P43/00A61P7/00
    • C07D231/18C07D401/12
    • Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
    • 式(I)化合物或其药学上可接受的衍生物,其中R 1和R 3独立代表H,C 1-6烷基 C 3-8环烷基或卤素; R 2表示C 1-6烷基,CF 3或芳基; a代表1或2; R 4,R 5,R 7和R 8独立地表示H,C 1-6 C 1-6烷基,C 1-6烷氧基,CN或卤素,或R 4和R 5或R 7 和它们所连接的环连接形成芳基或杂环稠环体系; X表示C或N; Y表示CH 2或O; R 6表示H,CN或卤素,条件是当X表示N时,R 6不存在。 这些化合物可用于治疗子宫内膜异位症,子宫肌瘤(平滑肌瘤),月经过多,子宫腺肌症,原发性和继发性痛经(包括性交疼痛,dyschexia和慢性盆腔疼痛症状)或慢性盆腔疼痛综合征。
    • 6. 发明授权
    • System and methods for processing and displaying aggregate status events for remote nodes
    • 用于处理和显示远程节点聚合状态事件的系统和方法
    • US07603458B1
    • 2009-10-13
    • US10674322
    • 2003-09-30
    • John C. SextonPaul BradleyHanna YehudaDavid Barta
    • John C. SextonPaul BradleyHanna YehudaDavid Barta
    • G06F15/173
    • H04L41/065H04L41/0213H04L41/046H04L41/0681H04L41/142H04L41/22H04L43/0817
    • A status monitoring and reporting mechanism which distinguishes more significant events and prominently displays events pertaining to nodes, interconnections, and other network entities which may present problems, and to suppresses benign messages which may not require immediate attention, provides an “at a glance” view of overall system health. By processing and displaying aggregate status events from a plurality of agent components to highlight the most severe and critical events from among a large volume of general status events allows an operator to quickly diagnose potential problems before detrimental results occur, and helps maintain a general efficient system health by isolating less efficient areas to allow for timely remedial action prior to failure. Various agents disseminated in a storage area network determine and report status events back to a central server. The server receives, aggregates, and processes the status events to display a status array indicative of overall system health.
    • 区分更重要事件并显着地显示有关可能存在问题的节点,互连和其他网络实体的事件以及抑制可能不需要立即注意的良性消息的状态监视和报告机制提供了“一目了然”视图 的整体系统健康。 通过处理和显示来自多个代理组件的聚合状态事件以突显来自大量一般状态事件中的最严重和关键的事件,允许操作者在有害的结果发生之前快速诊断潜在问题,并且有助于维持一般的有效系统 通过隔离效率较低的领域,以便在失败之前及时采取补救措施来保护健康。 在存储区域网络中传播的各种代理确定并将状态事件报告回中央服务器。 服务器接收,聚合和处理状态事件以显示指示整个系统运行状况的状态数组。
    • 10. 发明申请
    • Acoustically coupled resonators and method of making the same
    • 声耦合谐振器及其制作方法
    • US20060232361A1
    • 2006-10-19
    • US11109596
    • 2005-04-18
    • Kun WangPaul BradleyRichard Ruby
    • Kun WangPaul BradleyRichard Ruby
    • H03H9/72H03H9/56
    • H03H9/587H03H3/02H03H7/1708H03H9/0095H03H9/0571H03H9/583H03H9/584H03H9/706H03H2003/0428Y10T29/49002
    • An apparatus includes a substrate with a cavity and a two-stage resonator filter fabricated over the cavity. The two-stage resonator filter includes a first stage and a second stage. The first stage includes a first resonator and a second resonator, the second resonator acoustically coupled to the first resonator. The second stage includes a third resonator and a fourth resonator, the fourth resonator acoustically coupled to the third resonator. The second resonator and the third resonators are electrically coupled. A decoupling layer couples the first resonator and the second resonator. The decoupling layer extends between the third resonator and the fourth resonator. The first resonator and the fourth resonator are above the substrate. The decoupling layer is above the first resonator and the fourth resonator. The second resonator and the third resonators are above the decoupling layer.
    • 一种装置包括具有空腔的衬底和在空腔上制造的两级谐振器滤波器。 两级谐振滤波器包括第一级和第二级。 第一级包括第一谐振器和第二谐振器,第二谐振器声耦合到第一谐振器。 第二级包括第三谐振器和第四谐振器,第四谐振器声耦合到第三谐振器。 第二谐振器和第三谐振器电耦合。 去耦层耦合第一谐振器和第二谐振器。 解耦层在第三谐振器和第四谐振器之间延伸。 第一谐振器和第四谐振器在衬底之上。 去耦层位于第一谐振器和第四谐振器之上。 第二谐振器和第三谐振器在去耦层之上。